Peptide RX

back to claim graph

proof receipt / idea

Effect design run

GLP-1 receptor agonist for type-2 diabetes-like metabolic effect

grade C status designing receipt d39114e3c03e proof 17%

what this node claims

Effect design run

GLP-1 receptor agonist for type-2 diabetes-like metabolic effect

Open source surface

vertical proof spine

  1. 01 Effect design run idea / grade C / 47% 1 debt
  2. 02 GLP-1R target / grade B / 70% 1 debt

evidence / risk instrument

37%
thin proof
structure evidence gates risk export lineage 37
low debt pressure 18%
28%structuredebt
pLDDT pending
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
17%lineagedebt
incomplete spine

proof completeness

17% missing fold, alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

candidate count
0
matcher
platform_research
proof debt register

Visible limits, not hidden cleanup.

18%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

medium no candidate yet leave visible until a stronger public receipt resolves it
medium missing functional-site annotations link target annotation, GO term, or binding-site context

weakness and challenge edges

What would stop this from becoming stronger.

debt severity export claim strength next proof needed
no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it
missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context

what supports it

No upstream proof edge yet.

what it supports

effect run matched target idea:effect-run:6d89df5a-7637-49ff-b4c4-0237bd06d090 -> target:c6c265ea-7550-4914-a2ee-b295e4a1e476 targets / C / 0.52

Research-use boundary

This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.